Rodman & Renshaw Initiates Coverage On Journey Medical with Buy Rating, Announces Price Target of $9
Portfolio Pulse from Benzinga Newsdesk
Rodman & Renshaw has initiated coverage on Journey Medical (NASDAQ:DERM) with a Buy rating and set a price target of $9.
August 22, 2024 | 5:25 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Rodman & Renshaw has initiated coverage on Journey Medical with a Buy rating and a price target of $9, indicating potential upside.
The initiation of coverage with a Buy rating and a specific price target suggests positive sentiment from Rodman & Renshaw, which could lead to increased investor interest and a potential rise in DERM's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100